For example, while such measures are avoided in some cases, discontinuation is not regulated by laws.
Dose reduction and/or temporary interruption of regorafenib, or in severe or persistent cases, discontinuation of regorafenib should be considered (Table 3).
In all cases, discontinuation was initiated by the neurologist and were based on insufficient response (four patients, 22.2%) and side effects (nine patients, 50.0%).
Prompt treatment with corticosteroids or other immunosuppressive therapy, skipping a dose of ipilimumab, or in some cases discontinuation of ipilimumab therapy permitted resolution of the majority of severe events in a matter of days to weeks 22.
In five of 13 patients, movement disorders were the only reported adverse event at discontinuation (case 1, dyksinesia; case 2 dyskinesia and tardive dyskinesia, case 3, tardive dyskinesia; case 4, extrapyramidal disorder, hypertonia, hypokinesia; case 5, extrapyramidal disorder).
In the case of discontinuation, the patient incurs a treatment specific risk of suffering from discontinuation symptoms.
Runners will be censored in case of: discontinuation of the running schedule due to lack of motivation and/or time, health- and illness problems, and other personal concerns hindering further participation.
If this is the case, early discontinuation of oral anticoagulation may have adverse effects.
Therefore, in case of discontinuation, all efforts will be made to complete and report the observations as thoroughly as possible.
